Holen Sie sich die Stockscreener-App
10.83
3.84%
0.40
Schlusskurs vom Vortag:
$10.43
Offen:
$10.69
24-Stunden-Volumen:
17,962
Relative Volume:
0.09
Marktkapitalisierung:
$343.83M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-8.5276
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
-1.55%
1M Leistung:
-12.02%
6M Leistung:
+45.76%
1J Leistung:
-20.54%
1-Tages-Spanne:
$10.49
$10.78
1-Wochen-Bereich:
$9.56
$11.09
52-Wochen-Spanne:
$5.45
$15.77
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.78 | 343.83M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
126.15 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.81 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.33 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.08 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.64 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com
Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat
NeuroPACE at Leerink’s Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains NeuroPace stock target at $20 By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains NeuroPace stock target at $20 - Investing.com
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
Cantor Fitzgerald Expects Increased Earnings for NeuroPace - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
NeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - Defense World
NeuroPace Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeuroPace: Strong Financial Performance and Strategic Initiatives Drive Buy Rating - TipRanks
NeuroPace, Inc. Reports Strong 2024 Growth Despite Challenges - TipRanks
Cantor raises NeuroPace stock price target to $20, maintains overweight - Investing.com India
What 4 Analyst Ratings Have To Say About NeuroPace - Benzinga
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor raises NeuroPace stock price target to $20, maintains overweight By Investing.com - Investing.com South Africa
NeuroPace Q4 2024 revenue increases 19% to USD 21.5M - Medical Buyer
NeuroPace Inc.: Q4 Earnings Snapshot - Midland Daily News
NeuroPace Inc (NPCE) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
NeuroPace Reports Strong Growth and Strategic Advancements - TipRanks
Earnings call transcript: Neuropace Q4 2024 results beat forecasts - Investing.com India
NeuroPace reports Q4 EPS (18c), consensus (22c) - TipRanks
Neuropace Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neuropace Q4 2024 results beat forecasts By Investing.com - Investing.com UK
NeuroPace Inc SEC 10-K Report - TradingView
Neuropace earnings beat by $0.07, revenue topped estimates - Investing.com Australia
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results -March 04, 2025 at 04:54 pm EST - Marketscreener.com
NeuroPace stock rises on Q4 earnings beat, strong 2025 outlook By Investing.com - Investing.com Australia
NeuroPace stock rises on Q4 earnings beat, strong 2025 outlook - Investing.com India
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
NeuroPace Inc.: Q4 Earnings Snapshot -March 04, 2025 at 04:25 pm EST - Marketscreener.com
UPDATENeuroPace to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
When Will NeuroPace Reveal Its Next Strategic Moves? Key Investor Conference Date Set - StockTitan
NeuroPace, Inc. to Present at Leerink Partners 2025 Global Healthcare Conference - Nasdaq
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire Inc.
NeuroPace to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
How Will NeuroPace Position Its Epilepsy Treatment Future at Leerink's Healthcare Conference? - StockTitan
UPDATE – NeuroPace To Present At The Leerink Partners Global Healthcare Conference - Barchart
NeuroPace (NPCE) Projected to Post Earnings on Tuesday - Defense World
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells 78,334 Shares of Stock - MarketBeat
When the Price of (NPCE) Talks, People Listen - Stock Traders Daily
NeuroPace (NPCE) to Release Quarterly Earnings on Tuesday - MarketBeat
Neuropace Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.57%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):